Degrades BCL-XL in MOLT-4 T-ALL cells with unique selectivity for MOLT-4 cells compared to traditional BCL-XL inhibitors, suggesting that T-ALL can be improved by converting the inhibitor to PROTAC treatment window. The gene discussed is BCL2L1; the disease is acute lymphoblastic leukemia.